Patent: 7,772,208
✉ Email this page to a colleague
Summary for Patent: 7,772,208
Title: | 2\',3\'-dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
Abstract: | A method for the treatment or prevention of Flaviviridae infections, in particular, hepatitis C virus infection, in a host, and in particular, a human, is provided that includes administering an effective amount of a .beta.-L- or .beta.-D-2\',3\'-dideoxynucleoside or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable diluent or excipient. |
Inventor(s): | Schinazi; Raymond (Atlanta, GA), Striker; Robert (Madison, WI), Shi; Junxing (Duluth, GA) |
Assignee: | Pharmasset, Inc. (Princeton, NJ) Leland Stanford Junior University (Palo Alto, CA) Emory University (Atlanta, GA) |
Application Number: | 11/970,908 |
Patent Claims: | see list of patent claims |
Details for Patent 7,772,208
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Biogen Inc. | AVONEX | interferon beta-1a | For Injection | 103628 | 05/17/1996 | ⤷ Try a Trial | 2022-08-01 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 05/28/2003 | ⤷ Try a Trial | 2022-08-01 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 02/27/2012 | ⤷ Try a Trial | 2022-08-01 |
Kadmon Pharmaceuticals Llc | INFERGEN | interferon alfacon-1 | Injection | 103663 | 10/06/1997 | ⤷ Try a Trial | 2022-08-01 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 03/07/2002 | ⤷ Try a Trial | 2022-08-01 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 12/17/2004 | ⤷ Try a Trial | 2022-08-01 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 12/21/2012 | ⤷ Try a Trial | 2022-08-01 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |